UEGJournal Abstracts 2021 - 635

Other lower GI disorders
P0611
EFFECT OF BIFIDOBACTERIUM LONGUM 35624 ON DISEASE SEVERITY
AND QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME:
RESULTS OF THE FLORAVIE STUDY
J.M. Sabate1
, F. Iglicki2
1Hôpital Avicenne, AP-HP, Gastroenterology, Bobigny, France,
2Private Practice Gastroenterologist, Clichy, France
Contact E-Mail Address: jean-marc.sabate@aphp.fr
Introduction: Irritable bowel syndrome (IBS), which combines abdominal
pain and transit disorders affects 5% of the population and may be
responsible for an alteration of quality of life, especially in the most severe
forms. Some probiotics, such as Bifidobacterium longum 35624 (formerly
B. infantis) (1), have shown efficiency on IBS symptoms vs. placebo in
double blind randomized studies. However, in most of these studies, IBS
severity was not described or was minimal to moderate and quality of life
was not studied.
Aims & Methods: The aim of our observatory study was to describe in
real life the efficacy of Bifidobacterium longum 35624 on the IBS severity
and the quality of life of IBS patients. Patients with IBS (Rome IV criteria),
followed by gastroenterologists in private practice were included in the
prospective multicentre 'Floravie' study. Treatment with Bifidobacterium
longum 35624 (1 gel - 109
bacteria - per day for 30 days) was then initiated,
in the absence of other probiotic treatment, or recent modification
of treatment for IBS, or recent treatment that could have impacted gut microbiota
(such as antibiotics). The following data were evaluated before
treatment and after 30 days of treatment with B. longum 35624: demographic
characteristics of patients and disease, stool consistency (Bristol
scale), IBS severity (IBS-SSS, from 0 to 500; remission if <75; minimal severity
between 75 and 175, average between 175 and 300 and severe> 300)
and quality of life (IBS-QoL, score of 0 to 100, 100 being the best quality of
life), satisfaction regarding the treatment and adverse effects.
Results: From November 2018 to January 2020, 233 patients (mean age
51.4 years; women 71.2 %,) were included by 61 gastroenterologists (from
12 of the 13 French regions). Median disease duration was 8 years, IBS subtypes
were distributed as follows: IBS-C 30.5%; IBS-D 38.2%; IBS-M 26.2%,
and 5.2% of unspecified forms. IBS severity was minimal for 4.7%, moderate
for 48.1%, and 46.4% of patients had a severe IBS, 2 patients (0.9%) being
in remission. Sixty seven percent of patients had no other associated
pathology and 79% were not taking any other treatment.
Quality of life scores did not differ between subtypes but were correlated
with disease severity. After 30 days of treatment, there was a clinically significant
reduction in the severity of the disease (overall IBS-SSS score of
208 ± 104 vs. 303 ± 81 at baseline, p <0.001, with an improvement in each
of the 5 items) of equal magnitude in all transit subtypes resulting in a
change in severity level to less severe categories and remission in 57% of
patients.
Overall quality of life was also improved (IBS-QOL 68.8 ± 20.9 vs. 60.2 ±
20.5 at baseline; p <0.001) in each of its 8 dimensions, with a significant
clinical improvement (increase > 10 points) in 36.9% of patients, especially
those with most severe IBS at baseline (9.1% in case of minimal severity,
28.6% for moderate severity, and 49.1% in those with severe IBS). Treatment
tolerance was excellent and a large majority of patients (63.8%) were
satisfied with the treatment.
Conclusion: In this real-life study, Bifidobacterium longum 35624, a probiotic
with well-established superiority over placebo in two previous randomized
studies, reduced the severity of the IBS in patients whatever the
transit sub-types, and improved the quality of life of patients, especially in
those with the most severe forms of IBS over a 30-day period of treatment.
Acknowledgments: IBS patients and investigators involved in the FLORAVIE
study.
Vol. 9 | October 2021
References:
1. Whorwell et al. Efficacy of an Encapsulated Probiotic Bifidobacterium
infantis 35624 in Women with Irritable Bowel Syndrome. Am J Gastroenterol
2006; 101: 1581-1590
Disclosure: Dr. Sabate and Dr Iglicki report personal fees from Biocodex
during the conduct of the study;
Dr Sabate also reports personal fees from Biocodex, Kyowa Kirin, Norgine,
Mayoly Spindler, Arko Pharma, and from Tillots Pharma outside the submitted
work.
P0612
RESPONSES TO FAECAL MICROBIOTA TRANSPLANTATION IN FEMALE
AND MALE PATIENTS WITH IRRITABLE BOWEL SYNDROME
M. El-Salhy1
1
, C. Christina2
, J. Valeur3
, T. Hausken4
, J.G. Hatlebakk5
Stord Hospital Medical Clinic Dept. of Gastroenterology/University
of Bergen, Gastroenterology, Stord, Norway, 2
Oslo, Norway, 3
Genetic Analysis AS,
Institute, Oslo, Norway, 4
Lovisenberg Diakonale Hospital, Unger-Vetlesens
Haukeland University Hospital, Medical
Dept, Bergen, Norway, 5Haukeland University Hospital Dept. of
Medicine, Bergen, Norway
Contact E-Mail Address: magdy.elsalhy@sklbb.no
Introduction: The intestinal microbiota plays a pivotal role in the pathophysiology
of irritable bowel syndrome (IBS) and faecal microbiota transplantation
(FMT) is a promising intervention for IBS patients. There is a sex
difference in IBS, with a female: male ratio of 2:1. A sex difference in the
response to FMT has been reported recently in IBS patients (1).
Aims & Methods: The present study aimed at investigating whether there
is a sex difference in the response to FMT in terms of symptoms, dysbiosis,
bacteria and short chain fatty acids (SCFAs) profiles in the same cohort
of patients that we had investigated in our previous randomized doubleblind
placebo-controlled trial (RCT).
The study included 164 IBS patients (132 females and 32 males) who participated
in our previous RCT (2). These patients had moderate-to-severe
IBS symptoms belonging to the with diarrhoea-predominant (IBS-D), constipation-predominant
(IBS-C) and mixed diarrhoea and constipation
(IBS-M) subtypes. They belonged in three groups: placebo (own faeces),
and active treated group (30‐g or 60‐g super-donor faeces).
The patients completed the IBS Severity Scoring System (IBS‐SSS), Fatigue
Assessment Scale (FAS) and the IBS Quality of Life Scale (IBS‐QoL)
questionnaires at the baseline and 2 weeks, 1 month and 3 months after
FMT. They also provided faecal samples at the baseline and 1 month after
FMT. The faecal bacteria profile and dysbiosis were determined using a
16S rRNA gene PCR DNA amplification covering the variable genes V3-V9;
hybridization and probe labelling by single nucleotide extension and fluorescent
signal detection. The levels of SCFAs were determined by vaccum
distillation followed by gas chromatography.
Results: There was no sex difference in the response to FMT either in the
placebo group or active treated group. There was no difference between
females and males in either the placebo group or actively treated groups
in the total score of the IBS-SSS, FAS or IBS-QoL, in dysbiosis, or in the faecal
bacteria or SCFAs levels.
However, the response rates in females with diarrhoea-IBS-D was 90%
both 1 month, and 3 months after FMT. The corresponding values in males
were 42% both after 1 month and 3 months following FMT. The response
rates in females with IBS-D, 1 month and 3 months after FMT were significantly
higher than those of males (p=0.0003 in both).
There was no significant difference between females and males with IBSC
and IBS-M regarding the response rates at all the observation intervals.
Moreover, IBS-SSS total score in female patients with IBS-D was 177.8±94.9
635

UEGJournal Abstracts 2021

Table of Contents for the Digital Edition of UEGJournal Abstracts 2021